1206487-35-5

Basic information

• Product Name: 4,6-dibromopyridazin-3-amine
• Synonyms: 4,6-dibromopyridazin-3-amine;3-Amino-4,6-dibromopyridazine;4,6-Dibromo-3-pyridazinamine
• CAS NO: 1206487-35-5
• Molecular Formula: C₄H₃Br₂N₃
• Molecular Weight: 253
• Mol File: 1206487-35-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 376.6±37.0 °C(Predicted)
• Appearance: /
• Density: 2.287±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 1.93±0.10(Predicted)
• CAS DataBase Reference: 4,6-dibromopyridazin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dibromopyridazin-3-amine(1206487-35-5)
• EPA Substance Registry System: 4,6-dibromopyridazin-3-amine(1206487-35-5)

Safety Data

• Hazardous Substances Data: 1206487-35-5(Hazardous Substances Data)

Usage

General Description

4,6-dibromopyridazin-3-amine is a chemical compound with the molecular formula C4H4Br2N4. It is an organic compound that contains two bromine atoms and an amine group attached to a pyridazine ring. This chemical has potential applications in pharmaceutical research and development, as well as in the synthesis of other organic compounds. It is used as an intermediate in the production of various pharmaceuticals and agrochemicals. Additionally, it may also have some industrial uses in the manufacturing of certain materials. Due to its specific chemical structure, 4,6-dibromopyridazin-3-amine can exhibit unique chemical and physical properties that make it valuable for various scientific and commercial applications.

Upstream product

• 187973-60-0 6-iodopyridazine-3-amine 
• 88497-27-2 6-bromopyridazin-3-amine 

Downstream Products

• 1402608-82-5 tert-butyl (1-{4-[3-phenyl-6,8-dibromoimidazo[1,2-b]pyridazin-2-yl]-phenyl}cyclobutyl)carbamate 
• 1206487-36-6 6,8-dibromoimidazo[1,2-b]pyridazine 

Relevant articles and documents

PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS

The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.

SUBSTITUTED IMIDAZOPYRIDAZINES

The present invention relates to substituted imidazopyridazine compounds, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS

A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.